Related Experiment Video
Updated: May 6, 2026
Author Spotlight: Exploring Photodynamic Therapy with Curcumin in a Murine Model for Oral Candidiasis
Published on: October 27, 2023
Successful Treatment of Refractory Cutaneous Protothecosis With MAT2203, an Oral Lipid Nanocrystal Formulation of
Joseph Pechacek1, Monica M Schmitt1, Elise M N Ferrè1
1Fungal Pathogenesis Section, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Abstract:
Prototheca wickerhamii is a rare cause of cutaneous and systemic infection that requires long treatment courses with potentially toxic medications. We describe a patient with cutaneous protothecosis refractory to triazole monotherapy who experienced clinical and radiographic improvement with the novel oral lipid nanocrystal formulation of amphotericin B without experiencing toxicity.
Insights
Prototheca wickerhamii infections are rare and hard to treat. A novel oral amphotericin B formulation effectively treated a patient with resistant skin infection without toxicity.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Dermatology
Background:
- Prototheca wickerhamii causes rare, difficult-to-treat cutaneous and systemic infections.
- Standard treatments often require prolonged courses of potentially toxic medications.
More Related Videos
09:13Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
Published on: November 22, 2024
08:29Engineering Chimeric Antigen Receptor-Natural Killer Cells Targeting Fungal Infections Using the Non-viral Sleeping Beauty Transposon System
Published on: October 4, 2024
